Donepezil and memantine for moderate-to-severe Alzheimer's disease.
about
Behavioral and psychological symptoms of dementiaSimulated presence therapy for dementiaPotential drug-drug interactions in Alzheimer patients with behavioral symptomsThe impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy peopleRecent advances in the application of metabolomics to Alzheimer's Disease2012 -- That was the year that wasCombotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseEfficacy of memantine, donepezil, or their association in moderate-severe Alzheimer's disease: a review of clinical trialsMemantine monotherapy for Alzheimer's disease: a systematic review and meta-analysisPersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsNon-pharmacological cognitive intervention for aging and dementia: Current perspectivesMemantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's diseaseAlzheimer's disease: Targeting the Cholinergic SystemA fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's diseaseDementia.Dementia: timely diagnosis and early interventionInappropriate drugs in elderly patients with severe cognitive impairment: results from the shelter studyThe timing of drug funding announcements relative to elections: a case study involving dementia medicationsLong-term oral administration of hop flower extracts mitigates Alzheimer phenotypes in miceSystematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series.Drug repurposing from the perspective of pharmaceutical companies.Simulated presence therapy for dementia.Can zebrafish be used as animal model to study Alzheimer's disease?Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer).Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Alzheimer's disease drug-development pipeline: few candidates, frequent failuresEffects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer's diseasePharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Clinical significance in dementia research: a review of the literature.Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance.Systematic review and meta-analysis of combination therapy with cholinesterase inhibitors and memantine in Alzheimer's disease and other dementiasCurrent and future treatments for Alzheimer's diseaseThe impact of Medicare prescription drug coverage on the use of antidementia drugs.Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Preventing loss of independence through exercise (PLIÉ): a pilot clinical trial in older adults with dementia.The contribution of diseases to the male-female disability-survival paradox in the very old: results from the Newcastle 85+ study.Cattle encephalon glycoside and ignotin injection improves cognitive impairment in APPswe/PS1dE9 mice used as multitarget anti-Alzheimer's drug candidatesCombination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis
P2860
Q21129432-E7E9FEB0-0DA7-4F2A-B356-265170D506F3Q24187490-6A509DAC-2875-43AA-8747-F85A365E21C8Q26782490-DAA8A572-0514-4CC6-B756-F82869783909Q26799352-9E185F10-0C30-48BF-AD37-DB4518EDEE5FQ26828606-48CF1AF5-2CF1-437D-BE05-4EAB8B055957Q26829471-27DEAA75-98AA-4234-8A53-1339A7D787B3Q26829899-09F08B17-9530-4589-82E2-578C2F7EA2EDQ26851862-2886A09D-244A-4232-BCB7-66CBC0FF1481Q26861399-28998A3E-A015-485B-9B41-7B8E942A5A9EQ26997299-10661ABE-EDE7-4AA0-9944-752F0C03AA8DQ27023484-3DD3D853-1A6F-4FD9-AA33-8A0A7060FAFEQ27025207-FE6B9363-76DC-48F2-B109-01FCD6D3B352Q28070135-DC25BBED-77C4-4AA5-A7C6-D70204525D96Q28076715-280D47FB-2BC3-4D26-9954-EA6CEC0C33A6Q28081075-12598071-C593-4F6F-A2DD-E2C39F7B01D7Q28082444-1621D899-B525-4931-8EE2-55C40B601089Q28484216-CA9933CF-35E5-42BD-9D8E-76DE0D2E5329Q28486951-22AA60A1-484C-4905-8E5D-92FC7CC4AF7DQ28539305-904F445F-D1E8-4BAD-8E89-4107BF8C5233Q30400013-F105EA5B-7DBD-477B-849E-9AE2B40A2807Q30400634-971CC4DD-2F4C-4F5C-BE2D-5BA3C013DEA7Q30401151-25E9996F-4803-40E1-86D2-B0A8C01CEE74Q30458465-C7657444-12B2-4527-BC91-D4FC466072C1Q31155412-23523FD4-AA05-4BB8-99E0-E812AF3BC974Q33165801-B13B8C03-C9F7-478E-97C8-D7B6BF57B255Q33454879-E4907076-9558-41AE-97D6-038D4C0E06FBQ33556068-7346955B-9B59-4992-9B58-29AEDDCDACBFQ33892815-CA5FF5D1-E5E4-4A73-9C25-F52569502278Q34230445-AE7A269E-05C8-402F-941B-ADDB414D0054Q34327769-2F769ADD-D1F4-42C6-BF3B-61B61711D30BQ34404220-F5A86739-37C0-45DB-84CE-60D5B6BE8BA7Q34463351-762CCDD0-E9FA-45E5-99CA-B08422BAAAF0Q34528182-D2A6C9A9-C635-4075-9BF5-86D091A236D0Q34646921-662D1AE0-6771-4CBC-AC9B-39BD062D3985Q34690333-77960E69-AE4C-4006-A427-6F551BBE4C1DQ35006354-E8953B03-C323-49E5-AE1B-2FB768BA69E3Q35074465-6CEAA095-BCA6-43D3-A481-3D7F134AA4FFQ35091510-4202DE59-7E48-4257-8699-B174803C2814Q35167977-A30E3B06-0A1A-4F42-8FD9-98D808B461C1Q35224319-19936324-8EAE-455D-B5C6-D0B3D2893F61
P2860
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@ast
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@en
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@nl
type
label
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@ast
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@en
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@nl
prefLabel
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@ast
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@en
Donepezil and memantine for moderate-to-severe Alzheimer's disease.
@nl
P2093
P50
P356
P1476
Donepezil and memantine for moderate-to-severe Alzheimer's disease
@en
P2093
Ajay Macharouthu
Alan Hughes
Ashley Baldwin
Bart Sheehan
Caroline Onions
Cornelius Katona
Craig Ritchie
David Findlay
Edmund Juszczak
James Lindesay
P304
P356
10.1056/NEJMOA1106668
P407
P50
P577
2012-03-01T00:00:00Z